Quick Facts: Travotan (Travoprost Ophthalmic Solution)

Condition Managed	Primary Therapeutic Goal
Open-Angle Glaucoma	Assists in reducing intraocular pressure (IOP)
Ocular Hypertension	Aids in lowering elevated eye pressure (IOP)

---

What Travotan treats: main uses and benefits

Travotan (travoprost ophthalmic solution) is a prescription-only topical medication designated to address elevated fluid pressure within the eye. This medication is specifically indicated for the management of conditions where high eye pressure may be a concern.

Its primary therapeutic role is in supporting the reduction of intraocular pressure (IOP) in adult patients who have been diagnosed with open-angle glaucoma or ocular hypertension. Maintaining a supported reduction in IOP is a key management strategy for these conditions.

This treatment option may be considered as part of a regimen to manage elevated eye pressure. It can be utilized alone or in conjunction with other topical ophthalmic therapies to assist in achieving the target IOP. For detailed information on the approved uses of travoprost, patients and caregivers should consult professional medical resources. The appropriate use and duration of therapy should always be determined by a qualified healthcare professional. Consistent use as directed is important to support the continuous management of eye pressure.

Travotan is officially indicated for adult patients with open-angle glaucoma or ocular hypertension, including the elderly population, where no overall differences in use have been observed. Eligibility for patients with mild to severe hepatic or renal impairment is established, as regulatory documents state that no dosage adjustment is necessary.

Contraindications and Restrictions

• Contraindicated: The medicine is strictly contraindicated for patients with a known hypersensitivity to travoprost or any of its ingredients. It must not be used by women who are pregnant or attempting to become pregnant.
• Conditional Use: Women of child-bearing potential must have adequate contraceptive measures in place.
• Use Not Recommended: Use is not recommended in pediatric patients below the age of 16 years due to potential long-term safety concerns regarding increased pigmentation. Use by breast-feeding mothers is not recommended.
• Use with Caution: Caution is required in patients with active intraocular inflammation (e.g., iritis/uveitis) or in those with risk factors for macular edema, such as aphakic or pseudophakic patients with a torn posterior lens capsule.

Interactions with other medicines and products — Official Regulatory Information

The official interaction profile for Travotan (travoprost ophthalmic solution) is primarily based on its topical administration and negligible systemic exposure. Regulatory documents confirm a limited number of interaction constraints.

---

Documented Interaction Constraints

Interaction Type	Restriction or Requirement
Timing-Based Administration	Other Topical Ophthalmic Drugs must be administered at least five (5) minutes apart from travoprost.
Pharmacodynamic Restriction	Co-administration of travoprost or other Prostaglandin Analogs more than once daily is not permitted, as this may decrease the intraocular pressure lowering effect.
Systemic Exposure Profile	Due to the very low systemic exposure of the active acid, official labels do not document specific systemic drug-drug interactions (including those mediated by CYP enzymes or transporters).
Population-Specific Notes	No dosage adjustment is necessary for patients with mild to severe hepatic impairment or mild to severe renal impairment.

---

Official Regulatory Statements

• Co-administration with other topical ophthalmic products requires that the products must be administered at least five (5) minutes apart.
• Administration of travoprost or other prostaglandin analogs more than once daily may result in a decrease of the intraocular pressure lowering effect.
• Official regulatory documents do not document specific systemic drug-drug interactions, CYP-mediated interactions, or interactions with food, alcohol, or herbal products.

---

The official regulatory documents define the product's interaction structure primarily around its localized administration. This profile is characterized by mandatory timing rules for concurrent topical medications and a frequency-of-use restriction related to the class-specific pharmacodynamic response. The negligible systemic exposure of the active compound results in an interaction profile that excludes specific warnings for systemic drug-drug interactions involving metabolic enzymes or transporters.

Receptor Activation and Prodrug Hydrolysis

Travoprost is administered as an inactive prodrug (isopropyl ester) that must first be converted by local corneal esterase enzymes into its biologically active metabolite, travoprost free acid. This free acid then acts as a selective full agonist on the Prostaglandin F (FP) receptor, a type of G-protein coupled receptor situated within the ciliary muscle tissue. This receptor activation is the necessary starting point for the entire physiological cascade.

---

Extracellular Matrix Remodeling and Outflow Enhancement

Activation of the FP receptor initiates a signal that increases the activity of Matrix Metalloproteinases (MMPs). These MMPs are enzymes that remodel the Extracellular Matrix (ECM), the collagen-rich structure surrounding the ciliary muscle fibers. This remodeling increases the permeability of the tissue, physically creating and widening spaces between the muscle bundles.

---

Sustained Reduction of Fluid Resistance

The structural changes within the tissue lead directly to an increase in the facility of aqueous humor outflow, primarily through the uveoscleral pathway. By physically reducing the resistance of this pathway, the mechanism continuously modulates fluid flow from the anterior chamber of the eye. This results in the physiological consequence of a sustained reduction in intraocular pressure, maintained over a 24-hour cycle due to the mechanism's duration.

Travotan (travoprost ophthalmic solution) is a prescription medicine administered exclusively by the topical ocular route, meaning the solution is instilled directly into the affected eye(s). Its use is defined by a fixed, once-daily schedule for the long-term maintenance of reduced intraocular pressure (IOP).

Standard Administration Protocol

The standard, officially approved posology for travoprost 0.004% is one drop administered into the conjunctival sac of the affected eye(s) once daily. This dose should not be exceeded, as more frequent administration may diminish the IOP-lowering effect.

The medication is generally recommended for application in the evening to achieve the maximal pressure reduction effect, which typically occurs about 12 hours after administration. If a dose is missed, patients should continue with the next scheduled dose as planned and must not attempt to use extra drops to compensate.

Administration Conditions and Constraints

Condition	Official Instruction
Concomitant Eye Drops	If used with other topical ophthalmic drugs, instillations must be separated by at least five minutes.
Contact Lenses	Soft contact lenses must be removed prior to instillation and may be reinserted 15 minutes after use.
Technique	Nasolacrimal occlusion or gentle eyelid closing is advised after administration to limit systemic absorption. The dropper tip must not touch the eye or surrounding areas.

Population-Specific Dosing

No dosage adjustment is necessary for patients diagnosed with hepatic or renal impairment, across mild to severe cases. While generally indicated for adults, official prescribing information specifies that the same once-daily posology may be used for pediatric patients aged two months to under 18 years. The standard adult dose is maintained for elderly patients.

Research Evidence: Overview of Studies for Travotan

Evidence for use in Open-Angle Glaucoma

Research for Travotan (travoprost) in Open-Angle Glaucoma (OAG) was studied to assess patterns in elevated fluid pressure (IOP). The research primarily uses data from large, regulated studies called Randomized Controlled Trials (RCTs). The main focus of these trials was monitoring IOP measurements, which are used as a standard surrogate endpoint in glaucoma research. Studies reported patterns observed in the trials where IOP measurements were recorded in patients using Travoprost once daily. Comparative research examined whether Travoprost produced IOP measurements comparable to other prostaglandin analogs like latanoprost; findings indicate IOP measurements were comparable across study groups.

Evidence for use in Ocular Hypertension

Travoprost was evaluated in patients with Ocular Hypertension (OH), a condition where eye pressure is elevated without observable optic nerve damage. Research primarily examined IOP measurements over short and intermediate time intervals. Studies reported patterns observed in the trials indicating that measurements of IOP were collected in the observed populations. In comparative studies, the reported diurnal IOP measurements were often described as within the expected range across the daytime measurement points.

Comparative Studies with Other Treatments

Research describes that when compared to timolol (a beta-blocker), the IOP measurements observed in Travoprost studies did not always align in studies that ran for up to 9 or 12 months. When compared to other prostaglandin analogs, findings indicated IOP measurements were evaluated for equivalence across the study groups. Bioequivalence studies were conducted to confirm that newer formulations of Travoprost produced IOP measurements consistent with the original formulation.

Key Uncertainties and Research Gaps

The research evidence contributes to understanding the product’s effect on IOP but also reveals several limitations. The primary outcome studied is Intraocular Pressure (IOP) change. Since IOP is a surrogate endpoint, evidence does not directly characterize the drug's effect on long-term outcomes like preventing blindness. Data for certain groups, particularly infants and very young children, remain insufficient. The long-term evidence is limited regarding the maintenance of comparable IOP measurements over very long periods.

Common questions about Travotan (FAQ)

Q: Is Travotan the same as other glaucoma eye drops?

A: Travotan belongs to a specific group of medicines called prostaglandin analogs. While many types of eye drops are used for glaucoma, they may belong to other drug classes and work through different mechanisms to reduce eye pressure.

Q: What is the difference between Travotan and Xalatan?

A: Both Travotan (active ingredient: travoprost) and Xalatan (active ingredient: latanoprost) are in the same pharmacological class, which is prostaglandin analogs. They use different active chemical substances and may have different inactive components in their formulation, but both work to reduce intraocular pressure.

Q: Does Travotan cause headaches or dizziness?

A: Official regulatory documents indicate that headache has been reported as an adverse reaction in clinical studies, typically occurring in 1% to 5% of patients (uncommon). Dizziness is generally not listed as a common or frequent side effect in the primary safety information.

Q: Can Travotan be used while pregnant or breastfeeding?

A: Official product information states that the medicine is not recommended for use while pregnant or for women who are trying to become pregnant. The medicine is also not recommended for use while breastfeeding. Women of child-bearing potential are generally advised to use adequate contraceptive measures.

Q: Are there any common foods or drinks that interact with Travotan?

A: Due to the medicine being applied directly to the eye and resulting in very low systemic exposure (meaning minimal amount enters the rest of the body), official regulatory documents generally do not document specific systemic drug-drug interactions, including those involving common food items or alcohol.

Q: Is Travotan safe to use long-term?

A: Travotan is prescribed for the long-term management of elevated eye pressure. Official product information notes long-term use can be associated with the possibility of a permanent change to the iris color, which may develop gradually over time. Studies have indicated the IOP-lowering effect can be maintained over several years.

Q: Is Travotan available in generic form?

A: Yes, the active ingredient, travoprost ophthalmic solution 0.004%, is available from various manufacturers as a generic version, in addition to the brand-name formulations.

Q: Are there different strengths or concentrations of Travotan drops?

A: The most common and standard concentration is 0.004% of the active ingredient, travoprost. Other concentrations have been used in research or marketed in some regions, but the 0.004% solution is the formulation specified in the majority of official prescribing information.

Q: Is it safe to drive after putting in Travotan eye drops?

A: Official information advises caution because temporary blurred vision may occur immediately after the drops are instilled. If this occurs, patients are generally advised to not drive or operate machinery until their vision is clear.

Q: What is the half-life of Travotan's active ingredient?

A: According to official pharmacokinetics data, the active substance (travoprost free acid) is rapidly cleared from the bloodstream. The terminal half-life of the active compound in the plasma is very short, approximately 45 minutes.

Q: Is Travotan used to treat narrow-angle glaucoma?

A: No. Official indications specify the medicine is for open-angle glaucoma and ocular hypertension. Safety and effectiveness have not been established for other types, such as narrow-angle, angle-closure, or inflammatory glaucoma.

Q: Why do I need to close my eyes after applying the drop?

A: It is advised to close the eyelid or apply gentle pressure to the tear duct area after instillation to help limit systemic absorption. This technique helps to limit systemic absorption of the medicine by reducing the amount that drains into the nasal passages.

Q: Does alcohol consumption affect how Travotan works?

A: Official regulatory documents do not list specific systemic drug interactions with alcohol. This is due to the nature of the drug's topical administration, which results in very low systemic exposure to the active compound.

Q: Is it normal to feel a stinging sensation when using Travotan?

A: Common side effects reported in clinical trials include ocular reactions such as eye pain, eye discomfort, and eye irritation. These sensations may sometimes be described by users as a stinging feeling.

Q: What happens if Travotan gets into my mouth or on my skin?

A: The medicine can be absorbed through the skin. If any solution comes into contact with the skin, regulatory documents state it should be washed off straight away if contact occurs. This precaution is especially important for women who are pregnant or trying to become pregnant.

Q: Does Travotan help with the pain associated with high eye pressure?

A: The official indication of the medicine is the reduction of elevated intraocular pressure (IOP), and it is not specifically classified as a pain reliever. The primary therapeutic focus is pressure reduction.

Q: Can I stop using Travotan if my eye pressure looks normal?

A: Travotan is prescribed for the long-term maintenance of reduced intraocular pressure. Stopping treatment may cause the eye pressure to return to the elevated pre-treatment level.

Storage and Disposal Instructions for Travatan

All storage and disposal of Travatan (travoprost ophthalmic solution) must strictly follow the conditions defined in the official regulatory labeling.

---

Storage Conditions

Travatan must be stored at a controlled temperature range, typically 2 C to 25 C (36 F to 77 F), and kept below 30 C. It is mandatory to keep from freezing and protect the solution from excess heat and moisture. The medicine must remain in the original container and be kept tightly closed when not in use. For safety, always store it out of the sight and reach of children.

Stability and Disposal

The medicine has a limited in-use shelf-life; the opened container must be discarded four weeks after first opening. Any unused product or expired solution must be disposed of in accordance with local requirements. Patients should consult a pharmacist or healthcare professional for guidance on proper disposal.